Back to Search Start Over

Complexes of Ruthenium(II) as Promising Dual-Active Agents against Cancer and Viral Infections

Authors :
Assunta D’Amato
Annaluisa Mariconda
Domenico Iacopetta
Jessica Ceramella
Alessia Catalano
Maria Stefania Sinicropi
Pasquale Longo
Source :
Pharmaceuticals, Vol 16, Iss 12, p 1729 (2023)
Publication Year :
2023
Publisher :
MDPI AG, 2023.

Abstract

Poor responses to medical care and the failure of pharmacological treatment for many high-frequency diseases, such as cancer and viral infections, have been widely documented. In this context, numerous metal-based substances, including cisplatin, auranofin, various gold metallodrugs, and ruthenium complexes, are under study as possible anticancer and antiviral agents. The two Ru(III) and Ru(II) complexes, namely, BOLD-100 and RAPTA-C, are presently being studied in a clinical trial and preclinical studies evaluation, respectively, as anticancer agents. Interestingly, BOLD-100 has also recently demonstrated antiviral activity against SARS-CoV-2, which is the virus responsible for the COVID-19 pandemic. Over the last years, much effort has been dedicated to discovering new dual anticancer–antiviral agents. Ru-based complexes could be very suitable in this respect. Thus, this review focuses on the most recent studies regarding newly synthesized Ru(II) complexes for use as anticancer and/or antiviral agents.

Details

Language :
English
ISSN :
14248247
Volume :
16
Issue :
12
Database :
Directory of Open Access Journals
Journal :
Pharmaceuticals
Publication Type :
Academic Journal
Accession number :
edsdoj.827b7b9e43494c8eb1dd4064858256cf
Document Type :
article
Full Text :
https://doi.org/10.3390/ph16121729